Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

Topic: Plasma and spinal-fluid biomarkers

Context Alzheimer disease (AD) is characterized neuropathologically by the presence of amyloid beta-peptide (Abeta)-containing plaques and neurofibrillary tangles composed of abnormal tau protein. Considerable controversy exists as to whether the extent of accumulation of Abeta correlates with dementia and whether Abeta alterations precede or follow changes in tau. Objectives To determine whether accumulation of Abeta correlates with the earliest signs of cognitive deterioration and to define the relationship between Abeta accumulation and early tau changes. Design, setting, and patients Postmortem cross-sectional study of 79 nursing home residents with Clinical Dementia Rating (CDR) scale scores of 0.0 to 5.0 who died between 1986 and 1997, comparing the levels of Abeta variants in the cortices of the subjects with no (CDR score, 0.0 [n = 16]), questionable (CDR score, 0.5 [n = 11]), mild (CDR score, 1.0 [n = 22]), moderate (CDR score, 2.0 [n = 15]), or severe (CDR score, 4.0 or 5.0 [n = 15]) dementia. Main outcome measures Levels of total Abeta peptides with intact or truncated amino termini and ending in either amino acid 40 (A(beta)x-40) or 42 (A(beta)x-42) in 5 neocortical brain regions as well as levels of tau protein undergoing early conformational changes in frontal cortex, as a function of CDR score. Results The levels of both A(beta)x-40 and A(beta)x-42 were elevated even in cases classified as having questionable dementia (CDR score = 0.5), and increases of both peptides correlated with progression of dementia. Levels of the more fibril-prone A(beta)x-42 peptide were higher than those of A(beta)x-40 in nondemented cases and remained higher throughout progression of disease in all regions examined. Finally, increases in A(beta)x-40 and A(beta)x-42 precede significant tau pathology at least in the frontal cortex, an area chosen for examination because of the absence of neuritic changes in the absence of disease. Conclusions In this study, levels of total A(beta)x-40 and A(beta)x-42 were elevated early in dementia and levels of both peptides were strongly correlated with cognitive decline. Of particular interest, in the frontal cortex, Abeta was elevated before the occurrence of significant tau pathology. These results support an important role for Abeta in mediating initial pathogenic events in AD dementia and suggest that treatment strategies targeting the formation, accumulation, or cytotoxic effects of Abeta should be pursued.

@article{naslund2000-10735393,
  author  = {Näslund, J. and Haroutunian, V. and Mohs, R. and Davis, K. L. and Davies, P. and Greengard, P. and Buxbaum, J. D.},
  title   = {{Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline}},
  journal = {JAMA},
  year    = {2000},
  doi     = {10.1001/jama.283.12.1571},
  pmid    = {10735393},
  url     = {https://doi.org/10.1001/jama.283.12.1571}
}

Key findings

• Results The levels of both A(beta)x-40 and A(beta)x-42 were elevated even in cases classified as having questionable dementia (CDR score = 0.5), and increases of both peptides correlated with progression of dementia.
• Finally, increases in A(beta)x-40 and A(beta)x-42 precede significant tau pathology at least in the frontal cortex, an area chosen for examination because of the absence of neuritic changes in the absence of disease.
• Of particular interest, in the frontal cortex, Abeta was elevated before the occurrence of significant tau pathology.
• These results support an important role for Abeta in mediating initial pathogenic events in AD dementia and suggest that treatment strategies targeting the formation, accumulation, or cytotoxic effects of Abeta should be pursued.

Study details

• Study designcross-sectional
• Participants16
• Effect sizeor 5.0
• Evidence strengthLow

Read the original

• DOI: 10.1001/jama.283.12.1571
• PubMed: 10735393
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Related studies in Brain tissue and pathology

• Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation Nature medicine · 2005-03-20 · usefulness score 52/100
• Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline Journal of neuropathology and experimental neurology · 2003-12-01 · usefulness score 45/100
• Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report Nature medicine · 2003-03-17 · usefulness score 61/100
• Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017-02-28 · usefulness score 62/100
• Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease Neurology · 2010-10-20 · usefulness score 57/100
• Elevated TDP-43 serum levels associated with postoperative delirium following major cardiac surgery Brain Behavior & Immunity - Health · 2025-03-07 · usefulness score 47/100

Also tagged “blood-based”

698 studies in the library carry the topic tag “blood-based”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 698 tagged studies.

• A positive Alzheimer's blood biomarker is not a diagnosis: the presence-primacy-permission framework for plasma p-tau217 Annals of medicine and surgery (2012) · 2026-09-08 · usefulness score 45/100 · Biomarkers
• Predictive value of plasma p-tau217 for Alzheimer's dementia compared to other blood-based biomarkers EMBO molecular medicine · 2026-07-16 · usefulness score 75/100 · Biomarkers
• Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms Alzheimer's & dementia (Amsterdam, Netherlands) · 2024-01-09 · usefulness score 63/100 · Genetics

Similar studies

• The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia 2010 · Biomarkers
• Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease 2000 · Tau biomarkers
• Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness 2002 · Tau biomarkers
• Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals 2020 · Biomarkers
• Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease 1995 · Tau biomarkers
• The impact of amyloid-beta and tau on prospective cognitive decline in older individuals 2019 · Brain scans and imaging

More on Brain tissue and pathology

• A review that covers this ground Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease Brain pathology (Zurich, Switzerland) · 2008-04-01 · usefulness score 48/100
• Newest in this subject Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival Research Square · 2026-11-01 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject TMEM106B C-Terminal fragment aggregation exacerbates α-synuclein and TDP-43 proteinopathy phenotypes bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Brain tissue and pathology →